Therapies for Depressive and Anxiety Disorders : Market Research Report

Therapies for Depressive and Anxiety Disorders

Published by: BCC Research

Published: Feb. 1, 2010 - 179 Pages

CHAPTER ONE: INTRODUCTION: STUDY GOALS AND OBJECTIVES; REASONS FOR STUDY; SCOPE OF STUDY; METHODOLOGY AND INFORMATION SOURCES; ANALYST CREDENTIALS; RELATED BCC REPORTS; DISCLAIMER
CHAPTER TWO: EXECUTIVE SUMMARY: EXECUTIVE SUMMARY
CHAPTER THREE: INDUSTRY OVERVIEW: HISTORICAL PERSPECTIVE OF THE MENTAL HEALTH INDUSTRY; INTRODUCTION TO THE NERVOUS SYSTEM AND BRAIN; BLOOD-BRAIN BARRIER; DEMOGRAPHICS; PREVALENCE OF MENTAL DISORDERS; CHILDREN AND ADOLESCENTS; OLDER ADULTS; COSTS OF MENTAL ILLNESS; DEPRESSIVE DISORDERS; MAJOR DEPRESSION; Etiology and Neurobiology; Clinical Manifestations; BIPOLAR DISORDER; Etiology and Neurobiology; Clinical Manifestations; Bipolar I Disorder; Bipolar II Disorder; SEASONAL AFFECTIVE DISORDER; Clinical Manifestations; ANXIETY DISORDERS; Panic Disorder; Etiology and Neurobiology; Clinical Manifestations; Generalized Anxiety Disorder; Etiology and Neurobiology; Clinical Manifestations; Obsessive-Compulsive Disorder; Etiology and Neurobiology; Clinical Manifestations; Specific and Social Phobias; Post-Traumatic Stress Disorder; GENERIC INFLUENCE; ELDERLY IMPACT; DEPRESSION; ANXIETY; CHILDREN AND ADOLESCENT IMPACT; DEPRESSION; Symptoms of Depression in Children; ANXIETY; ALTERNATIVE AND COMPLEMENTARY THERAPIES; ST. JOHN’S WORT (HYPERFORIN AND HYPERICIN); VALERIAN ROOT; 5-HTP; RHODIOLA ROSEA; SAM-E; BACOPA; GINSENG; B VITAMINS - B1, B3, B5, B6, B9, AND B12; ZINC; MAGNESIUM; KAVA KAVA; OVERUSE OF ANTIDEPRESSANTS—ANOTHER VIEW; LEGISLATIVE ISSUES; COMPLIANCE ISSUES; PRESCRIBING TRENDS; DEPRESSION RISK DUE TO BRAIN THINNING; SUICIDAL BEHAVIOR AND ANTIDEPRESSANTS; NOVEL APPROACH IN TEEN SUICIDE; COMBINATION THERAPY; REMOTE SUPPORT FOR DEPRESSION; TREATMENTS AND PRODUCTS FOR DEPRESSIVE DISORDERS; PRESCRIPTION PRODUCTS; Selective Serotonin Reuptake Inhibitors; Side Effects; Pharmacologics; Serotonin-Norepinephrine Reuptake Inhibitors; Tricyclic Antidepressants; Chemical Aspects; Mechanism of Action; Actions and Side Effects; Pharmacologics; Monoamine Inhibitors; Chemical Aspects; Pharmacologics; Side Effects; Others; Marketed Antidepressants; ALTERNATIVE TREATMENTS; Light Therapy; Electroconvulsive Therapy; Acupressure; Acupuncture; Biofeedback; Nutrition; Reflexology; Self-Help Groups; Animal-Assisted Therapies; Expressive Therapies; Art Therapy; Dance/Movement Therapy; Music/Sound Therapy; Guided Imagery or Visualization; Massage Therapy; Technology-Based Applications; Telemedicine; Telephone Counseling; Electronic Communications; Radio Psychiatry; Vagus Nerve Stimulation (VNS); Transcranial Magnetic Stimulation (TMS); Deep Brain Stimulation; TREATMENTS AND PRODUCTS FOR ANXIETY DISORDERS; PRESCRIPTION PRODUCTS; Barbiturates; Benzodiazepines; Tricyclic Antidepressants; Selective Serotonin Reuptake Inhibitors; Serotonin-Norepinephrine Reuptake Inhibitors; Effexor; Cymbalta; Antihistamines; Anticonvulsants/Bipolar; Lamictal; Lithium; Beta-Blockers; Antipsychotics; Abilify; BuSpar; Geodon; Risperdal; Seroquel; Zyprexa
CHAPTER FOUR: MARKET SIZE AND GROWTH: TOTAL MARKET; Total Antidepressant and Antianxiety Drug Market by Product Classification; TOTAL ANTIDEPRESSANT AND ANTIANXIETY DRUG MARKET BY GEOGRAPHIC SEGMENTS; DEPRESSION MARKET; ANTIDEPRESSANT DRUG MARKET BY PRODUCT CLASSIFICATION; ANTIDEPRESSANT DRUG MARKET BY GEOGRAPHIC SEGMENTS; United States; European Union; Japan; Rest of World; ANTIANXIETY MARKET; ANTIANXIETY DRUG MARKET BY PRODUCT CLASSIFICATION; ANTIANXIETY DRUG MARKET BY GEOGRAPHIC SEGMENTS; United States; European Union; Japan; Rest of World
CHAPTER FIVE: RESEARCH AND DEVELOPMENT: GEODON; GEPIRONE ER; RISPERDAL CONSTA; SAPHRIS; SEROQUEL XR; TRAZODONE ONCE DAILY; AGI0178; CORLUX; INVEGA; LU AA21004; LYRICA; NUVIGIL; SAREDUTANT; VILAZODONE; TABLE 27 THERAPIES IN DEVELOPMENT FOR DEPRESSION AND ANXIETY, 2009; NOVEL PRODUCTS IN DEVELOPMENT
CHAPTER SIX: COMPETITIVE ANALYSIS: TOTAL COMPETITIVE ANALYSIS; DEPRESSION COMPETITIVE ANALYSIS; ANTIANXIETY COMPETITIVE ANALYSIS
CHAPTER SEVEN: PATENT ANALYSIS: TABLE 33 SELECTED MANUFACTURER PATENTS FOR TREATMENT OF DEPRESSION AND ANXIETY
CHAPTER EIGHT: COMPANY PROFILES: ASTRAZENECA; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; BRISTOL-MYERS SQUIBB COMPANY; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; DOV PHARMACEUTICAL, INC.; BRIEF HISTORY; PRODUCTS; RESEARCH AND DEVELOPMENT; ELI LILLY & COMPANY; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; FABRE-KRAMER PHARMACEUTICALS, INC.; BRIEF HISTORY; PRODUCTS; RESEARCH AND DEVELOPMENT; FOREST PHARMACEUTICALS, INC.; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; GLAXOSMITHKLINE; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; JAZZ PHARMACEUTICALS, INC.; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; JOHNSON & JOHNSON; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; H. LUNDBECK A/S; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; MERCK & COMPANY, INC.; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; PFIZER, INC.; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; ROCHE, INC.; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; SANOFI-AVENTIS; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; SEPRACOR, INC.; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; SCHERING-PLOUGH CORP; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT; WYETH; BRIEF HISTORY; PRODUCTS; COMPANY REVENUE HISTORY; RESEARCH AND DEVELOPMENT
APPENDIX A: ALTERNATIVE APPROACHES TO MENTAL HEALTH ORGANIZATIONS
APPENDIX B: COMPANY LISTINGS
LIST OF TABLES: SUMMARY TABLE TOTAL MARKET FOR DEPRESSIVE AND ANXIETY; DISORDERS, THROUGH 2014 ($ MILLIONS); TABLE 1 WORLD POPULATION BY SELECTED GEOGRAPHICAL; REGION, 2008-2050 (MILLIONS); TABLE 2 ESTIMATED WORLD POPULATION BY AGE AND; GEOGRAPHICAL REGION, 2008 (MILLIONS); TABLE 3 POPULATION OVER 65 BY YEAR AND REGION, 2008-2050 (%); TABLE 4 BEST ESTIMATE 1-YEAR PREVALENCE RATES BASED ON; ECA AND NCS, AGES 18-54 (%); TABLE 5 PERCENTAGE OF INDIVIDUALS 12 YEARS AND OLDER; WITH DEPRESSION BY DEMOGRAPHIC CHARACTERISTIC—AGE,; SEX, AND RACE, U.S. 2006 (%); TABLE 6 PERCENTAGE OF INDIVIDUALS WITH DEPRESSION BY AGE; AND POVERTY STATUS, UNITED STATES 2006 (%); TABLE 7 INDIVIDUALS 12 YEAR OF AGE AND OLDER REPORTING; DIFFICULTY WITH THEIR WORK, HOME, AND SOCIAL ACTIVITIES; BY SEX AND DEPRESSION SEVERITY, UNITED STATES, 2006 (%); TABLE 8 INDIVIDUALS 12 YEARS OF AGE AND OLDER CONTACTING; A MENTAL HEALTH PROFESSIONAL IN THE PAST 12 MONTHS, BY; DEPRESSION SEVERITY, UNITED STATES 2006 (%); TABLE 9 BEST ESTIMATE PREVALENCE RATES BASED ON; EPIDEMIOLOGICAL CATCHMENT AREA, AGE 55+ (%); TABLE 10 RISK FACTORS FOR MAJOR DEPRESSIVE AND BIPOLAR; DISORDERS; TABLE 11 PREFRONTAL CORTEX AND SEROTONIN; INTERCONNECTIONS: IMPLICATIONS IN DEPRESSION; TABLE 12 CLINICAL NAMES FOR COMMON PHOBIAS; TABLE 13 SELECTED MARKETED ANTIDEPRESSANT DRUGS ($; MILLIONS); TABLE 14 SELECTED MARKETED ANTIANXIETY DRUGS; TABLE 15 TOTAL MARKET FOR DEPRESSIVE AND ANXIETY; DISORDERS, THROUGH 2014 ($ MILLIONS); TABLE 16 TOTAL MARKET SHARE BY CATEGORY, 2009 AND 2014 (%); TABLE 17 GLOBAL MARKET SIZE OF THERAPIES FOR DEPRESSIVE; AND ANXIETY DISORDERS BY REGION, THROUGH 2014 ($; MILLIONS); TABLE 18 TOTAL MARKET SHARE BY REGION, 2009 AND 2014 (%); TABLE 19 GLOBAL MARKET FOR ANTIDEPRESSANTS BY PRODUCT,; THROUGH 2014 ($ MILLIONS); TABLE 20 GLOBAL MARKET SHARE OF ANTIDEPRESSANTS BY; PRODUCT, THROUGH 2014 (%); TABLE 21 GLOBAL MARKET FOR ANTIDEPRESSANTS BY REGION,; 2007-2014 ($ MILLIONS); TABLE 22 GLOBAL MARKET SHARE OF GLOBAL ANTIDEPRESSANTS; BY REGION, 2007-2014 (%); TABLE 23 GLOBAL MARKET FOR ANTIANXIETY DRUGS BY PRODUCT; TYPE, THROUGH 2014 ($ MILLIONS); TABLE 24 GLOBAL MARKET SHARE OF ANTIANXIETY DRUGS BY; PRODUCT TYPE, 2007-2014 (%); TABLE 25 GLOBAL MARKET SIZE OF ANTIANXIETY DRUGS BY; REGION, THROUGH 2014 ($ MILLIONS); TABLE 26 GLOBAL MARKET SHARE OF GLOBAL ANTIANXIETY; DRUGS BY REGION, 2007-2014 (%); TABLE 27 THERAPIES IN DEVELOPMENT FOR DEPRESSION AND; ANXIETY, 2009; TABLE 28 TOTAL COMPETITIVE ANALYSIS OF THERAPIES FOR; DEPRESSION AND ANXIETY DISORDERS BY DRUG; MANUFACTURER MARKET SHARE, 2008 ($ MILLIONS/%); TABLE 29 COMPETITIVE ANALYSIS OF THERAPIES FOR; DEPRESSION DISORDERS BY DRUG MANUFACTURER MARKET; SHARE, 2008 ($ MILLIONS/%); TABLE 30 COMPETITIVE ANALYSIS OF THERAPIES FOR; DEPRESSION DISORDERS BY THE TOP FOUR DRUG; MANUFACTURERS’ MARKET SHARE, 2008 ($ MILLIONS/%); TABLE 31 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY; DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 ($; MILLIONS/%); TABLE 32 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY; DISORDERS BY THE TOP FOUR DRUG MANUFACTURER MARKET; SHARE, 2008 ($ MILLIONS/%); TABLE 33 SELECTED MANUFACTURER PATENTS FOR TREATMENT; OF DEPRESSION AND ANXIETY; TABLE 34 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 35 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 36 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 37 COMPANY REVENUES, 2007 AND 2008 ($ BILLIONS); TABLE 38 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 39 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 40 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 41 COMPANY REVENUES 2007 AND 2008 ($ MILLIONS); TABLE 42 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 43 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 44 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 45 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 46 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 47 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 48 COMPANY REVENUES, 2007 AND 2008 ($ MILLIONS); TABLE 49 COMPANY LISTINGS
LIST OF FIGURES: SUMMARY FIGURE TOTAL MARKET FOR DEPRESSIVE AND; ANXIETY DISORDERS, 2007-2014 ($ MILLIONS); FIGURE 1 WORLD POPULATION BY SELECTED GEOGRAPHICAL; REGION, 2008-2050 (MILLIONS); FIGURE 2 ESTIMATED WORLD POPULATION BY AGE AND; GEOGRAPHICAL REGION, 2008 (MILLIONS); FIGURE 3 POPULATION OVER 65 BY YEAR AND REGION, 2008-2050; FIGURE 4 TOTAL MARKET FOR DEPRESSIVE AND ANXIETY; DISORDERS, 2007-2014 ($ MILLIONS); FIGURE 5 TOTAL MARKET SHARE BY CATEGORY, 2009 AND 2014 (%); FIGURE 6 GLOBAL MARKET SIZE OF THERAPIES FOR DEPRESSIVE; AND ANXIETY DISORDERS BY REGION, 2007-2014 ($ MILLIONS); FIGURE 7 TOTAL MARKET SHARE BY REGION, 2009 AND 2014 (%); FIGURE 8 GLOBAL MARKET FOR ANTIDEPRESSANTS BY PRODUCT,; 2007-2014 ($ MILLIONS); FIGURE 9 GLOBAL MARKET SHARE OF ANTIDEPRESSANTS BY; PRODUCT, 2007-2014 (%); FIGURE 10 GLOBAL MARKET FOR ANTIDEPRESSANTS BY REGION,; 2007-2014 ($ MILLIONS); FIGURE 11 GLOBAL MARKET SHARE OF GLOBAL; ANTIDEPRESSANTS BY REGION, 2007-2014 (%); FIGURE 12 GLOBAL MARKET FOR ANTIANXIETY DRUGS BY; PRODUCT TYPE, 2007-2014 ($ MILLIONS); FIGURE 13 GLOBAL MARKET SHARE OF ANTIANXIETY DRUGS BY; PRODUCT TYPE, 2007-2014 (%); FIGURE 14 GLOBAL MARKET SIZE OF ANTIANXIETY DRUGS BY; REGION, 2007-2014 ($ MILLIONS); FIGURE 15 GLOBAL MARKET SHARE OF GLOBAL ANTIANXIETY; DRUGS BY REGION, 2007-2014 (%); FIGURE 16 TOTAL COMPETITIVE ANALYSIS OF THERAPIES FOR; DEPRESSION AND ANXIETY DISORDERS BY DRUG; MANUFACTURER MARKET SHARE, 2008 (%); FIGURE 17 COMPETITIVE ANALYSIS OF THERAPIES FOR; DEPRESSION DISORDERS BY DRUG MANUFACTURER MARKET; SHARE, 2008 (%); FIGURE 18 COMPETITIVE ANALYSIS OF THERAPIES FOR; DEPRESSION DISORDERS BY THE TOP FOUR DRUG; MANUFACTURERS’ MARKET SHARE, 2008 (%); FIGURE 19 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY; DISORDERS BY DRUG MANUFACTURER MARKET SHARE, 2008 (%)
LIST OF FIGURES: FIGURE 20 COMPETITIVE ANALYSIS OF THERAPIES FOR ANXIETY; DISORDERS BY THE TOP FOUR DRUG MANUFACTURER MARKET; SHARE, 2008 (%)

Abstract

THIS REPORT:

Analyzes the current global markets for depressive and anxiety disorder treatments, with data for 2008, estimates for 2009, and projections, with compound annual growth rates (CAGRs), through 2014
Identifies the number of people globally diagnosed with depressive and anxiety disorders
Examines the markets for Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), tricyclic antidepressants, and other drugs used to treat depressive and anxiety disorders
Covers the market potential for novel antidepressants, including triple update inhibitors, and their mechanisms of action
Describes regulatory and economic issues
Reviews the industry and its structure, and the many companies involved in providing depressive and anxiety disorder medications.

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

2/15/2012 - 32

Therapies for Depressive and Anxiety Disorders

Table of Contents

Abstract